In the era of combination antiretroviral therapy, survival of human immunodeficiency virus (HIV)-positive individuals has increased; however, patients continue to have central nervous system (CNS) abnormalities that reduce quality of life. HIV-associated presumed neuroretinal disorder (HIV-NRD) is a visual abnormality that occurs in about 10%-15% of patients with AIDS who do not have ocular opportunistic infections. HIV-NRD is characterized by reduced contrast sensitivity [1] [2] [3] , reduced color sensitivity [4] [5] [6] , and deficits in visual fields [7, 8] in the absence of impaired visual acuity. HIV-NRD may also compromise reading speed and reduce quality of life [9] .
The etiology of HIV-NRD is unknown, but cytokine dysregulation and chronic inflammation are considered likely cofactors. Genetic studies show that risk in European Americans is associated with mutations that are expected to decrease production of interleukin 10 (IL-10), an anti-inflammatory cytokine. Genetic markers include single-nucleotide polymorphisms (SNPs) in introns of the IL-10 receptor and an IL-10 receptor 1 (IL10R1) haplotype [10] . The nongenetic risk factors for HIV-NRD include age, race, a history of injection drug use (IDU), lower hemoglobin, decreasing Karnofsky score, and low CD4 + T-cell count [3] . Due to shared routes of transmission, many HIV-positive patients are also infected with the hepatitis C virus (HCV). Chronic HCV infection causes systemic inflammation [11] and increases mortality in HIV-positive patients by 35%-50% [12] . Both cell culture studies [13] and analysis of patient specimens indicate that HCV is present within the CNS and replicates there [14] [15] [16] [17] [18] . HCV is reported to have CNS effects that include reduced learning and memory abilities [14, [19] [20] [21] [22] . These deficits may improve in patients who clear HCV infection [23] . Despite successful HIV management, patients coinfected with HCV have an increased risk of neurocognitive dysfunction [24] [25] [26] and HIV-associated dementia [20] .
Because HCV is proinflammatory and penetrates the CNS, this study examined the impact of HCV infection on the prevalence and incidence of HIV-NRD in a large cohort of AIDS patients enrolled in the Longitudinal Studies of the Ocular Complications of AIDS (LSOCA). LSOCA is one of only a few cohort studies limited to persons diagnosed with AIDS, but without further exclusion criteria. It focuses exclusively on the era following the introduction of combination antiretroviral therapy. Because of the associations between HIV-NRD and the IL-10 signaling pathway, genetic associations between 4 IL10R1 SNPs and HCV risk were also examined.
METHODS

Study Subjects and Design
At enrollment, subjects in LSOCA were aged ≥13 years with a diagnosis of AIDS according to the 1993 definition of the Centers for Disease Control and Prevention (CDC). The LSOCA population is similar in age, race, and sex to the US AIDS population, except it has a lower percentage of patients with a history of IDU [27, 28] . At enrollment, demographic information and past medical history were obtained and physical and ophthalmologic examinations were performed by a LSOCA-certified ophthalmologist [28] . Ophthalmologic examinations were conducted at each visit.
Follow-up occurred every 3 months for patients with an ocular opportunistic infection (eg, cytomegalovirus retinitis [CMV-R]) and every 6 months otherwise. Most HIV type 1 (HIV-1) RNA assays were performed using the Roche Amplicor system. All baseline samples were tested for anti-HCV antibodies using the third-generation enzyme immunoassay version 2.0 (Abbott). HCV RNA testing was performed on all samples that tested positive for anti-HCV antibodies and on all samples from injection drug users, using the Roche COBAS AMPLICOR Hepatitis C Virus Test, version 2.0 (lower limit of detection, 50 IU/mL), except as noted previously; we estimate that this testing strategy identified about 93% of the patients with HCV RNA in serum [12] . Patients with HCV RNA were considered to have chronic infection, and patients with anti-HCV antibodies but without detectable HCV RNA were considered to have cleared a previous infection. The liver fibrosis stage was estimated in 451 subjects for whom data were available by calculating the aspartate aminotransferase platelet ratio index (APRI) score; a score ≥1.45 was used to distinguish minimal from advanced fibrosis/cirrhosis [29] . Polymorphisms in the IL10R1 gene that occur at relatively high frequency (minor allele frequency ≥3% in the general population) and are predicted to change amino acids and thus to influence IL-10 signaling were determined in 902 patients, as previously described [10] . The genotyping success rate was at least 95% for each SNP examined. This study was approved by the institutional review board at each center, and all patients gave written informed consent.
Data Analysis
Data available as of 31 December 2011 were included. HIV-NRD was defined as <1.50 log contrast sensitivity units. Among the 2393 subjects enrolled in LSOCA, 1576 were included in the analyses of HIV-NRD prevalence and 1220 were included in the analyses of HIV-NRD incidence (Supplementary Figure 1) . Because decreased visual acuity (eg, from an ocular infection or from media opacities) decreases contrast sensitivity and does not indicate HIV-NRD, 815 patients were excluded from the analysis carried out to determine HIV-NRD prevalence (Table 1) and from the analysis carried out to analyze the factors associated with HIV-NRD prevalence (Table 2) because they had ocular opportunistic infection(s) (n = 536), visual acuity <20/40 (n = 18), or lacked data regarding HCV status (n = 261). An additional 356 were excluded from the analysis of factors associated with HIV-NRD incidence (Table 3 ) because they had HIV-NRD at baseline or lacked follow-up data.
The population characteristics at enrollment were calculated by HIV-NRD status. Race/ethnicity was analyzed as white/nonHispanic versus all others. The associations between each characteristic and HIV-NRD status were assessed using χ 2 tests.
Unadjusted and adjusted logistic regression was used to identify factors associated with prevalent HIV-NRD at enrollment. The adjusted model included all baseline risk factors shown in Table 2 : HCV serostatus, age (dichotomized at the median age of 43 years), sex, race, HIV exposure category (dichotomized as IDU vs all others), CD4 + T-cell count, HIV load, highly active antiretroviral therapy use, HIV retinopathy status, and platelet count. The cumulative incidence (1 -survival) Kaplan-Meier curves were compared for HCV uninfected, cleared, and chronic. Unadjusted and adjusted Cox regression was used to identify factors associated with incident HIV-NRD. Follow-up time was calculated as the time from study entry to first HIV-NRD event in either eye or censoring (death, 31 December 2011, or to the date of the last study contact for patients who were lost to follow-up). Sensitivity analyses were performed to examine the hazard ratio (HR) for the first 3 years of follow-up versus later time points, and to determine the impact of censoring data when both eyes had <20/40 acuity and/or developed cataract. During the study, the Pelli-Robson charts were replaced at the clinics due to wear. The manufacturing process for the charts was changed in 2005, which resulted in patients' ability to read up to 6 additional letters. The new version was not in universal use until May 2010. Sensitivity analyses were performed to determine the impact of censoring data at December 2006 and at 2010. Censoring of the data at 2006 or at 2010 resulted in no substantive changes in interpretation and therefore results are shown not making any adjustments for manufacturing changes in the chart. Statistical analyses were performed with SAS software, version 9.2 (SAS Institute Inc, Cary, North Carolina) and R software version 2.13.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Risk Factors for HIV-NRD at Baseline
The study group included 244 patients with HIV-NRD and 1332 patients without HIV-NRD (Table 1) . Patients with HIV-NRD at baseline were more likely to have chronic HCV infection (P < .001), to be female (P = .004), to be nonwhite (P < .001), to have a history of IDU (P = .006), and to have a CD4 + T-cell count ≤100 cells/µL (P = .024). In an adjusted multivariable logistic regression model, prevalent HIV-NRD was significantly positively associated with 3 factors: chronic HCV infection (odds ratio Table 2 ). A subset analysis was performed on 476 subjects for whom data were available to assess the impact of liver fibrosis stage on the association between HIV-NRD and chronic HCV infection. In a logistic regression model of HIV-NRD that controlled for APRI ≥1.45, the magnitude of the association between HIV-NRD and HCV for chronic versus no markers of HCV was similar to the original analysis (OR, 1.64; 95% CI, .88-3.05; P = .16), although no longer statistically significant with this reduced sample size. HIV-NRD was not significantly associated with APRI ≥1.45 (OR, 1.50 [95% CI, .56-4.01; P = .43; Supplementary Table 1) .
Risk Factors for the Development of HIV-NRD
The development of HIV-NRD was analyzed in 1220 subjects with a median follow-up of 4.9 years (interquartile range [IQR], 2.4-8.8). There were 263 incident cases of HIV-NRD. In an adjusted Cox proportional hazards regression model, incident HIV-NRD was significantly associated with 4 factors: chronic HCV infection (hazard ratio [HR], 1.64; 95% CI, 1.14-2.37), age ≥43 years (HR, 1.59; 95% CI, 1.22-2.06), female sex (HR = 1.65; CI, 1.22-2.24), and HIV load >10 000 copies/mL ( Table 3 ). The association between chronic HCV infection and HIV-NRD remained significant in sensitivity analyses that investigated the impact of (1) censoring data when both eyes have <20/40 acuity and/or developed cataract, (2) censoring data at December 2006, (3) censoring data at 2010 (Supplementary  Table 2 ). Kaplan-Meier curves of the cumulative incidence of HIV-NRD are shown in Figure 1 . These data show the positive association between chronic HCV infection and the development of HIV-NRD expected based on the data in Table 3 and suggest that cleared HCV infection might increase the risk of HIV-NRD in a time-variant manner. This possibility was investigated through a sensitivity analysis of the Cox regression results (Supplementary Table 2 ). For patients with cleared HCV HIV-associated neuroretinal disorder was defined as <1.50 log contrast sensitivity units. Participants without ocular opportunistic infections, with at least 1 eye with visual acuity of 20/40 or better and without cataract, and with available HCV data are included.
Abbreviations: CI, confidence interval; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OR, odds ratio. a Unadjusted and adjusted logistic regression results, P value calculated using Wald χ infection, in an unadjusted model that allowed the HR to change at 3 years after enrollment, the HR for the first 3 years was 2.07 (95% CI, 1.14-3.74; P = .017), whereas the subsequent HR was 0.33 (95% CI, .05-2.37; P = .269). The interaction between cleared HCV infection and time had a P value of .08, showing a trend toward a time-variable effect of HCV infection and subsequent clearance. For comparison, the interaction between chronic HCV infection and time had a P value of .65, indicating that the risk associated with chronic infection was less variable over time.
A subset analysis was performed on 342 subjects to assess the impact of liver fibrosis stage on the association between the development of HIV-NRD and chronic HCV infection. In a regression model that controlled for APRI ≥1.45, the HR was 1.42, similar to the HR in the main analysis (1.64); however, the 95% CI and P value (.74-2.74 and P = .30, respectively) did not show a statistically significant relationship between HIV-NRD and chronic HCV infection. Incident HIV-NRD was significantly associated with APRI ≥1.45 (HR, 4.72; 95% CI, 2.22-10.01; P < .01), raising the possibility that advanced liver disease, some factor associated with advanced liver disease such as inflammation, or some factor associated with HIV/AIDS such as pancytopenia/thrombocytopenia increases the risk of HIV-NRD (Supplementary Table 1 ). 
IL10R1 Polymorphisms Are Associated With HCV Infection
Four SNPs in the IL10R1 gene were examined for associations with chronic HCV infection using Fisher exact test. The number of patients who were eligible for this analysis and had data for at least 1 SNP was 902. The availability of data varied from 860 to 887 for the 4 SNPs analyzed (Supplementary  Table 3 ). Of these patients, 140 had prevalent NRD at baseline. Three of the 4 SNPs had significant associations with chronic HCV infection in 1 or more of the populations examined. The rs2228055 SNP was associated with HCV infection in the total study group (P = .02) and in white patients (P = .01); rs2229113 trended toward significance in the total study group (P = .07) and was significant in white patients (P = .04); and rs3135932 was significant in white patients (P = .01) ( Table 4 ). The similar trend of HCV association observed for rs2229113 and rs3135932 may be due to the strong linkage disequilibrium they have with each other in European Americans (Supplementary Table 3 ). The rs2229114 SNP was not associated with HCV. None of the 4 SNPs was associated with baseline HIV-NRD (P > .10; data not shown). The distribution of allele frequencies of IL-10R1 SNPs was very different between European Americans and African Americans (Supplementary Table 3 ). Among African Americans, the frequencies of variant alleles were much lower, resulting in greatly reduced statistical power to detect any association with HCV susceptibility. In addition, the linkage disequilibrium pattern observed in European Americans was not observed in African Americans. 
DISCUSSION
In a large cohort of patients with CDC-defined AIDS, this study demonstrated that chronic HCV infection increased the risk of having HIV-NRD at enrollment and the risk of developing HIV-NRD over time. In addition to having chronic HCV infection, patients with HIV-NRD at enrollment were more likely to be female, to be of nonwhite race, to have a history of IDU, and to have CD4 + T cells ≤100 cells/µL. The risk of developing HIV-NRD was higher in patients aged >43 years (the median of the population). It was also higher in females and in patients with detectable HIV load. Several of the risk factors for prevalent and/or incident HIV-NRD are consistent with prior evidence that inflammation and cytokine dysregulation play an etiological role in the development of this impairment. Low CD4 + count, higher HIV load, age, and HCV infection are all associated with increased inflammation and/or decreased adaptive immune responses; females are predisposed to autoimmune disorders, which often involve proinflammatory cytokines. IL-10 is an important anti-inflammatory cytokine. IL-10R1 is the subunit of the IL-10 receptor complex that binds IL-10, mediating its biological effects. The 4 SNPs in the IL10R1 gene examined in this study were chosen because they cause an amino acid substitution. Three of the 4 SNPs were associated with chronic HCV infection in 1 or more populations. The variant rs2228055 allele leads to an isoleucine to valine mutation at residue 203, which lies close to the cell membrane where the loss of the additional methyl group present on isoleucine may decrease receptor function [30] . The rs2229113 allele replaces an arginine with glycine at residue 330 in the cytoplasmic domain of the receptor, causing a loss-of-function mutation [31] . Similarly, the variant rs3135932 allele replaces serine-138 with glycine, leading to a conformational change in the extracellular domain of the protein and reduced function [32] . The rs2228055 SNP was significantly associated with chronic HCV infection in the total study group, whereas rs3135932 and rs2229113, which are in strong linkage disequilibrium with each other, were significantly associated with HCV infection in white patients only. Although the same variants may have a similar effect in African Americans, we did not have sufficient statistical power to detect such an association. These findings support earlier studies showing associations between rs2228055 and HCV viral persistence [33] and between rs3135932 and rs2229113 and HCV progression [34] . Polymorphisms in the IL-10 receptor leading to decreased IL-10 signaling and therefore increased inflammation may promote HCV persistence and disease progression. IL-10 promoter region variants associated with reduced IL-10 signaling have already been shown to increase susceptibility to HIV-NRD [10] , indicating the importance of regulation of inflam-mation in HIV-NRD susceptibility. Reduced IL-10 signaling can decrease TNF-α suppression [35] , increasing the risk of inflammatory myelin damage in the optic nerve, which leads to a visual dysfunction similar to that observed in patients with HIV-NRD. We did not find an association between the IL-10R1 SNPs and HIV-NRD. It is possible that these SNPs are associated with HIV-NRD, but the limited sample size prevented us from observing this association.
The strengths of this study include the long and detailed follow-up of a large cohort of patients, the use of both antibody and viral RNA testing to establish HCV infection status, and the use of trained and expert ophthalmologists to detect HIV-NRD and other visual impairments. In addition, genetic testing was focused on a single gene, IL10R1, reducing the probability of detecting associations based on chance. The study also had some limitations, including the reliance of baseline testing to establish HCV infection status, the lack of complete data about liver fibrosis markers and IL10R1 genotype, and manufacturing changes during follow-up in the eye charts used to assess contrast sensitivity.
In summary, HCV infection increases the risk of HIV-NRD. Inflammation may be the mechanistic link between HCV infection and HIV-NRD, although it is also possible that HCV contributes more directly by infecting ocular tissues, thereby reducing their integrity. Adequate vision is important for maintaining a high quality of life. Reducing systemic infections such as HCV infection, by treating appropriately selected patients, may decrease HIV-NRD and benefit patients with HIV/AIDS.
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